NEW YORK – Drugs targeting chemokine receptors may be able to subdue the hyperactive immune response observed in critical COVID-19 patients, according to a new single-cell analysis of airway samples obtained from patients.
NEW YORK – Drugs targeting chemokine receptors may be able to subdue the hyperactive immune response observed in critical COVID-19 patients, according to a new single-cell analysis of airway samples obtained from patients.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.
Privacy Policy. Terms & Conditions. . Copyright © 2021 GenomeWeb, a business unit of Crain Communications. All Rights Reserved.